NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 176)
Posted On: 01/12/2021 3:23:42 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient outcomes. A recent article discussing this reads, “POAI realizes that ‘just genomics’ is not enough to deliver personalized therapeutic options. The company believes that a multi-omic approach to disease, or one that gathers data from multiple levels such as genome, epigenome, transcriptome, proteome and metabolome, offers a much greater chance of success. With that in mind, Predictive Oncology is addressing cancer, specifically ovarian cancer, by leveraging the synergies of two of its wholly owned subsidiaries — Helomics and TumorGenesis — to bring precision medicine to the space.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient outcomes. A recent article discussing this reads, “POAI realizes that ‘just genomics’ is not enough to deliver personalized therapeutic options. The company believes that a multi-omic approach to disease, or one that gathers data from multiple levels such as genome, epigenome, transcriptome, proteome and metabolome, offers a much greater chance of success. With that in mind, Predictive Oncology is addressing cancer, specifically ovarian cancer, by leveraging the synergies of two of its wholly owned subsidiaries — Helomics and TumorGenesis — to bring precision medicine to the space.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼